UNSPSC 51382504: Timegadine

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C20H23N5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1XR74J44UL, chemically known as guanidine, n-cyclohexyl-n-(2-methyl-4-quinolinyl)-n-2-thiazolyl- but generally known as timegadine, which bears US NIH Compound Identifier 68902. European Medicines Agency schedules Timegadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11062MIG.

UNSPSC 51382504 Timegadine is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, over-the-counter medications, and generic multi-source drugs for distribution through authorized wholesale channels and direct delivery to county health facilities. The code captures procurement activity across health departments, cooperative purchasing alliances, and county government health initiatives seeking to supply emergency response medications, community health programs, and pharmacy benefit systems. Issuing bodies include county health departments (such as Seminole County, Florida), state health and human services commissions, and multistate cooperative purchasing consortiums that coordinate procurement across participating jurisdictions. Recent solicitations reflect a mix of direct-purchase contracts for specific therapeutic products and strategic market-intelligence gathering to inform larger pharmacy benefit programs, with vendors typically required to maintain pharmaceutical manufacturing certifications, comply with drug supply chain security regulations, and demonstrate pricing competitiveness across multiple dosage forms and packaging configurations.

Recent activity concentrates in Florida and Minnesota, with additional involvement from Texas and Oregon through cooperative purchasing vehicles. Seminole County, Florida released IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, response due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities through three authorized wholesalers, with proposals due March 26, 2026 and contract awards effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, signaling state-level interest in alternative pharmacy benefit procurement models beyond traditional PBM arrangements.